» Articles » PMID: 24763823

Implication of K-ras and P53 in Colorectal Cancer Carcinogenesis in Tunisian Population Cohort

Overview
Journal Tumour Biol
Publisher Sage Publications
Specialty Oncology
Date 2014 Apr 26
PMID 24763823
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

According to the multistep route of genetic alterations in the colorectal adenoma-carcinoma sequence, the complex K-ras/p53 mutation is one of the first alterations to occur and represent an important genetic event in colorectal cancer (CRC). An evaluation of the mutation spectra in K-ras and p53 gene was effected in 167 Tunisian patients with sporadic CRC to determine whether our populations have similar pattern of genetic alteration as in Maghrebin's population. Mutation patterns of codon 12-13 of K-ras and exon 5-8 of p53 were analyzed by immunohistochemistry and PCR-SSCP and confirmed by sequencing. Mutations in the K-ras gene were detected in 31.13 % and affect the women more than the men (p = 0.008). Immunostaining showed that expression of p21 ras was correlated with the advanced age (p = 0.004), whereas loss of signal was associated with mucinous histotype (p = 0.003). Kaplan-Meier survival curve found that patients with the K-ras mutation had a shorter survival compared with patients without mutation (p = 0.005). Alteration in p53 was seen in 17.4 % of patients and affects three hot spot codons such as 175, 245, and 248. Overexpression of p53 was seen in 34.1 % and correlated with tumor node metastasis (TNM) advanced stage (p = 0.037) and mucinous histotype (p = 0.001). A high concordance between p53 expression and alteration (p<0.005) was shown. Concomitant mutations in K-ras and p53 gene were detected in only 4 % of tumors. K-ras and p53 undergo separate pathways in colorectal tumorogenesis. Interestingly, mutations in the K-ras gene might be considered a valuable prognostic factor correlated to poor outcome. p53 gene alterations were rather low in our set, and methylation pattern of p53 is required to elucidate the molecular basis of this protein in CRC.

Citing Articles

Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review.

Benmokhtar S, Laraqui A, Hilali F, Bajjou T, El Zaitouni S, Jafari M Clin Med Insights Oncol. 2024; 18:11795549241255651.

PMID: 38798959 PMC: 11128178. DOI: 10.1177/11795549241255651.


Correlation Between DCAMKL-1 Protein Expression and K-ras Gene Mutation in Colorectal Cancer.

Wu X, Li S, Yang Y, Hu J, Yang T Cancer Manag Res. 2024; 16:11-21.

PMID: 38196736 PMC: 10775797. DOI: 10.2147/CMAR.S440845.


Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series.

Mahdi Y, Khmou M, Souadka A, El Agouri H, Ech-Charif S, Mounjid C BMC Gastroenterol. 2023; 23(1):193.

PMID: 37277698 PMC: 10240782. DOI: 10.1186/s12876-023-02694-7.


Clinical Significance of Somatic Mutations in RAS/RAF/MAPK Signaling Pathway in Moroccan and North African Colorectal Cancer Patients.

Benmokhtar S, Laraqui A, El Boukhrissi F, Hilali F, Bajjou T, Jafari M Asian Pac J Cancer Prev. 2022; 23(11):3725-3733.

PMID: 36444585 PMC: 9930961. DOI: 10.31557/APJCP.2022.23.11.3725.


Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa.

Jafari M, Laraqui A, Baba W, Benmokhtar S, El Zaitouni S, Ait Ali A BMC Cancer. 2022; 22(1):1142.

PMID: 36344948 PMC: 9639273. DOI: 10.1186/s12885-022-10235-w.


References
1.
Dix B, Robbins P, Carrello S, House A, Iacopetta B . Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer. 1994; 70(4):585-90. PMC: 2033416. DOI: 10.1038/bjc.1994.355. View

2.
Munro A, Lain S, Lane D . P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005; 92(3):434-44. PMC: 2362083. DOI: 10.1038/sj.bjc.6602358. View

3.
Andreyev H, Norman A, Cunningham D, Oates J, Dix B, Iacopetta B . Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001; 85(5):692-6. PMC: 2364126. DOI: 10.1054/bjoc.2001.1964. View

4.
Cripps K, Purdie C, Carder P, White S, Komine K, Bird C . A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene. 1994; 9(9):2739-43. View

5.
Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith D, Goh H . Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer. 2000; 36(16):2053-60. DOI: 10.1016/s0959-8049(00)00285-9. View